Corcept Therapeutics Incorporated
CORTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Corcept Therapeutics Incorporated focuses on Biotechnology services and products. Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Valued at $9.28B, CORT is a mid-cap name in its sector. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Market Cap
$9.28B
Beta
0.40
P/E (TTM)
190.80
P/E (Fwd)
19.49
EPS (TTM)
$0.45
EPS (Fwd)
$4.41
ROE
8.2%
ROA
0.5%
Cash
$308.2M
Total Debt
$9.4M
Free CF
$77.4M
52W Change
18.4%
Annual Financials
Cash vs Debt
Where CORT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CORT finished 32.55% above its 150-day moving average ($83.11) and 53.51% above its 200-day moving average ($71.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CORT overbought or oversold?
At the October 19, 2026 close, CORT's RSI(14) was 40.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $308.2M in cash comfortably exceeding the $9.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $77.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 8.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $401.9M (2022) to $761.4M (2025), reflecting a 89% increase over the period.
CORT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CORT has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Corcept Therapeutics Incorporated and its sector.